ITGR vs. MASI, LIVN, TMDX, CNMD, INMD, SLNO, ALKS, PRGO, IMVT, and CBAY
Should you be buying Integer stock or one of its competitors? The main competitors of Integer include Masimo (MASI), LivaNova (LIVN), TransMedics Group (TMDX), CONMED (CNMD), InMode (INMD), Soleno Therapeutics (SLNO), Alkermes (ALKS), Perrigo (PRGO), Immunovant (IMVT), and CymaBay Therapeutics (CBAY). These companies are all part of the "medical" sector.
Masimo (NASDAQ:MASI) and Integer (NYSE:ITGR) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, community ranking, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.
Integer has lower revenue, but higher earnings than Masimo. Integer is trading at a lower price-to-earnings ratio than Masimo, indicating that it is currently the more affordable of the two stocks.
In the previous week, Masimo had 1 more articles in the media than Integer. MarketBeat recorded 12 mentions for Masimo and 11 mentions for Integer. Masimo's average media sentiment score of 0.48 beat Integer's score of 0.35 indicating that Integer is being referred to more favorably in the news media.
Masimo has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500. Comparatively, Integer has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500.
Integer has a net margin of 6.01% compared to Integer's net margin of 3.98%. Integer's return on equity of 13.77% beat Masimo's return on equity.
86.0% of Masimo shares are held by institutional investors. Comparatively, 99.3% of Integer shares are held by institutional investors. 9.7% of Masimo shares are held by company insiders. Comparatively, 2.0% of Integer shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Masimo currently has a consensus price target of $137.43, indicating a potential upside of 0.31%. Integer has a consensus price target of $120.50, indicating a potential upside of 8.30%. Given Masimo's stronger consensus rating and higher probable upside, analysts clearly believe Integer is more favorable than Masimo.
Masimo received 78 more outperform votes than Integer when rated by MarketBeat users. Likewise, 64.02% of users gave Masimo an outperform vote while only 63.39% of users gave Integer an outperform vote.
Summary
Masimo and Integer tied by winning 9 of the 18 factors compared between the two stocks.
Get Integer News Delivered to You Automatically
Sign up to receive the latest news and ratings for ITGR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ITGR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools